Cargando…

Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

Severe acute respiratory syndrome (SARS) caused by a novel coronavirus-2 (CoV-2), also known as COVID-19, has spread rapidly worldwide since it is recognized as a public health emergency and has now been declared a pandemic on March 11, 2020, by the World Health Organization. The genome of SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asif, Muhammad, Amir, Muhammad, Hussain, Abrar, Achakzai, Niaz M., Natesan Pushparaj, Peter, Rasool, Mahmood
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239670/ https://www.ncbi.nlm.nih.gov/pubmed/35777011 http://dx.doi.org/10.1097/MD.0000000000029660

Ejemplares similares

Cytogenetical and hematological analysis of chronic myelogenous leukemia patients with a novel case 52XX, t (1;9;22) (q23.3; q34; q11.2), +6, +8, i(9) (q10;q10), +18,+19,+21+der22 t(9;22)(q34;q11)
por: Asif, Muhammad, et al.
Publicado: (2022)

Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients
por: Rasool, Mahmood, et al.
Publicado: (2021)

Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations
por: Asif, Muhammad, et al.
Publicado: (2021)

Deciphering SARS CoV-2-associated pathways from RNA sequencing data of COVID-19-infected A549 cells and potential therapeutics using in silico methods
por: Natesan Pushparaj, Peter, et al.
Publicado: (2022)

Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
por: Iqbal, Zafar, et al.
Publicado: (2020)

A Novel Four-Way Complex Variant Translocation Involving Chromosome 46,XY,t(4;9;19;22)(q25:q34;p13.3;q11.2) in a Chronic Myeloid Leukemia Patient
por: Asif, Muhammad, et al.
Publicado: (2016)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
por: Pokorny, Rebecca, et al.
Publicado: (2022)

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Role of the antineoplastic drug bleomycin based on toxicogenomic-DNA damage inducing (TGx-DDI) genomic biomarkers data: A meta-analysis
por: Pushparaj, Peter Natesan, et al.
Publicado: (2023)

Exploration of potential molecular mechanisms and genotoxicity of anti-cancer drugs using next generation knowledge discovery methods
por: Pushparaj, Peter Natesan, et al.
Publicado: (2023)

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
por: DeAngelo, D J
Publicado: (2012)

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
por: Wieczorek, Agnieszka, et al.
Publicado: (2016)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Recurrent ventricular fibrillation with different tyrosine kinase inhibitors for chronic myeloid leukemia
por: Prashar, Abhisheik, et al.
Publicado: (2020)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2019)

The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Saydam, Guray, et al.
Publicado: (2022)

Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy
por: Rasool, Mahmood, et al.
Publicado: (2014)

Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Sato, T, et al.
Publicado: (2014)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
por: Halbach, Sebastian, et al.
Publicado: (2016)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
por: Petrushev, Bobe, et al.
Publicado: (2016)

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
por: Stuckey, Ruth, et al.
Publicado: (2020)

Involvement of Oxidative Stress in Resistance to Tyrosine-Kinase Inhibitors Therapy in Chronic Myeloid Leukemia
por: PASCU (VÎNTURIŞ), EMILIA GEORGIANA, et al.
Publicado: (2020)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
por: Moschovi, Maria, et al.
Publicado: (2021)

Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
por: Castillo, Dan Ran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uha1mgn7oc8k55hqgag8t6ioua